Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.66 |
| ▸ | CDK2 | P24941 | 3/20 | 0.56 |
| ▸ | PI4KA | P42356 | 2/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31350217 | 1.00 | PDPK1 (0.66) | PDPK1GDACDK2PI4KAPI4K2B | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.79 | PDPK1 (1.00) | PDPK1GDACDK2PI4KAPI4K2B | |
| SCHEMBL532461 | 0.79 | CDK2 (0.66) | PDPK1GDACDK2PI4KAPI4K2B | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2PI4KAPI4K2B | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2PI4KAPI4K2B | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2PI4KAPI4K2B | |
| SCHEMBL8851 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2PI4KAPI4K2B | |
| SCHEMBL19780 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2PI4KAPI4K2B | |
| SCHEMBL16147074 | 0.76 | CDK2 (0.47) | PDPK1GDACDK2PI4KAPI4K2B | |
| SCHEMBL2352414 | 0.76 | DPP4 (0.61) | PDPK1GDACDK2XDHDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| US-20110015383-A1 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2011-01-20 | — | — | US | claimed |
| US-20100137576-A1 | 5' O [(N ACYL)AMIDOPHOSPHATE] AND 5' O [(N ACYL)AMIDOTHIOPHOSPHATE] AND 5' O [(N ACYL)AMIDODITHIOPHOSPHATE] AND 5' O [(N ACYL)AMIDOSELENOPHOSPHATE] DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MILEKULARNYCHI MAKROMOLEKULARNYCH, P (PL) | 2010-06-03 | — | — | US | claimed |
| EP-2170918-A2 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | Centrum Badan Molekularnych I Makromolekularnych Pan (PL) | 2010-04-07 | — | — | EP | claimed |
| EP-2097430-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[N- ACYL)AMIDOSELENOPHOSPHATE-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | Centrum Badan Molekularnych I Makromolekularnych Pan (PL) | 2009-09-09 | — | — | EP | claimed |
| WO-2009005382-A2 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2009-01-08 | — | — | WO | claimed |
| WO-2008048128-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[(N- ACYL)AMIDOSELENOPHOSPHATE]-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2008-04-24 | — | — | WO | claimed |
| EP-4731186-A2 | METHODS AND COMPOSITIONS FOR TREATING EPITHELIAL DISEASES | The Regents of the University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024263919-A2 | METHODS AND COMPOSITIONS FOR TREATING EPITHELIAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230013636-A1 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES WITH FIBROSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-19 | — | — | US | disclosed |
| CN-115297850-A | Exosome-based treatment for liver fibrosis and other fibrosis-related diseases | 得克萨斯州大学系统董事会 | 2022-11-04 | — | — | CN | disclosed |
| EP-4069205-A1 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES ASSOCIATED WITH FIBROSIS | Board of Regents, The University of Texas System (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220064732-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | BPGBIO, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20210252036-A1 | METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) | THLIVERIS, ANDREW T. | 2021-08-19 | — | — | US | disclosed |
| CN-108645832-B | SERS chip and preparation method and application thereof | 苏州英菲尼纳米科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3849543-A1 | METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) | Berg LLC (US) | 2021-07-21 | — | — | EP | disclosed |
| CN-112996504-A | Methods of treating cancer by inhibiting ubiquitin conjugating enzyme E2K (UBE2K) | 博格有限责任公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021113761-A1 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES ASSOCIATED WITH FIBROSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-10 | — | — | WO | disclosed |
| US-11001891-B2 | Methods for treating Parkinson's disease | BERG LLC (US) | 2021-05-11 | — | — | US | disclosed |
| WO-2020055906-A1 | METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) | BERG LLC (US) | 2020-03-19 | — | — | WO | disclosed |
| EP-3538095-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | Berg LLC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-2931319-B1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | MODERNATX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2854865-B1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | BERG LLC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10023864-B2 | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta | BERG LLC (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2018090054-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | BERG LLC (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180135129-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | BERG, KARA ANN | 2018-05-17 | — | — | US | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170166891-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | BERG PHARMA LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3168304-A1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | Ophthotech Corporation (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-3165606-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3152307-A2 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | Berg LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9533002-B2 | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β | BERG LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION | 2016-09-15 | — | — | US | disclosed |
| EP-1919930-B1 | NEW NUCLEIC ACID BASE PAIRS | DAKO DENMARK AS (DK) | 2016-09-14 | — | — | EP | disclosed |
| EP-3028707-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150353930-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | BERG LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150202288-A1 | Combination Therapy for the Treatment of Ocular Neovascular Disorders | EYETECH PHARMACEUTICALS, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202289-A1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | EYETECH PHARMACEUTICALS, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150182623-A1 | Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist | Integrity Bio, Inc. | 2015-07-02 | — | — | US | disclosed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150157709-A1 | Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist | Integrity Bio, Inc. | 2015-06-11 | — | — | US | disclosed |
| EP-2854844-A2 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST | Ophthotech Corporation (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2854865-A2 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | Berg LLC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8916570-B2 | A3 adenosine receptor agonists and antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-20140294816-A1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | EYETECH PHARMACEUTICALS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140242082-A1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | OPHTHOTECH CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140179621-A1 | Methods for Treating or Preventing Ophthalmological Diseases | OPHTHOTECH CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140154266-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | BERG PHARMA LLC (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2013181495-A2 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST | OPHTHOTECH CORPORATION (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130323242-A1 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST | OPHTHOTECH CORP. (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2013177535-A2 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | BERG PHARMA LLC (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20120184569-A1 | A3 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-07-19 | — | — | US | disclosed |
| US-8206707-B2 | Combination therapy for the treatment of ocular neovascular disorders | OPHTHOTECH CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-8187597-B2 | Combination therapy for the treatment of ocular neovascular disorders | OPHTHOTECH CORPORATION (US) | 2012-05-29 | — | — | US | disclosed |
| EP-1660057-B1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | OPHTHOTECH CORP (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120100136-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2432476-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110200593-A1 | Combination Therapy for the Treatment of Ocular Neovascular Disorders | OPHTHOTECH CORPORATION | 2011-08-18 | — | — | US | disclosed |
| EP-2281885-A1 | Combination therapy for the treatment of ocular neovascular disorders | Ophthotech Corporation (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20110015383-A1 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2011-01-20 | — | — | US | disclosed |
| WO-2010127029-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
| US-7785784-B2 | Detection of oligonucleotides by dual hybridization | Eyetech, Inc. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7759472-B2 | Administering platelet derived growth factor antagonist and endothelial growth factor antagonist | OPHTHOTECH CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100137576-A1 | 5' O [(N ACYL)AMIDOPHOSPHATE] AND 5' O [(N ACYL)AMIDOTHIOPHOSPHATE] AND 5' O [(N ACYL)AMIDODITHIOPHOSPHATE] AND 5' O [(N ACYL)AMIDOSELENOPHOSPHATE] DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MILEKULARNYCHI MAKROMOLEKULARNYCH, P (PL) | 2010-06-03 | — | — | US | disclosed |
| US-20100129364-A1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | OPHTHOTECH CORPORATION (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100119522-A1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | OPHTHOTECH CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100111942-A1 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | OPHTHOTECH CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2170918-A2 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | Centrum Badan Molekularnych I Makromolekularnych Pan (PL) | 2010-04-07 | — | — | EP | disclosed |
| EP-2170918-A2 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | Centrum Badan Molekularnych I Makromolekularnych Pan (PL) | 2010-04-07 | — | — | EP | disclosed |
| US-7645871-B2 | Tumor inhibition by modulating sprouty expression of activity | MICHIGAN STATE UNIVERSITY (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2099497-A2 | ENHANCED RETINAL DELIVERY OF A NUCLEIC ACID THROUGH IONTOPHORESIS | Eyegate Pharma SA (FR) | 2009-09-16 | — | — | EP | disclosed |
| EP-2097430-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[N- ACYL)AMIDOSELENOPHOSPHATE-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | Centrum Badan Molekularnych I Makromolekularnych Pan (PL) | 2009-09-09 | — | — | EP | disclosed |
| EP-2097430-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[N- ACYL)AMIDOSELENOPHOSPHATE-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | Centrum Badan Molekularnych I Makromolekularnych Pan (PL) | 2009-09-09 | — | — | EP | disclosed |
| US-20090098139-A1 | Combination therapy for the treatment of neovascular disorders | OLDTECH, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093432-A1 | TUMOR INHIBITION BY MODULATING SPROUTY EXPRESSION OR ACTIVITY | MICHIGAN STATE UNIVERSITY | 2009-04-09 | — | — | US | disclosed |
| US-7514549-B2 | Tumor inhibition by modulating sprouty expression or activity | MICHIGAN STATE UNIVERSITY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090088721-A1 | Enhanced retinal delivery of a nucleic acid through iontophoresis | EYEGATE PHARMA S.A.S. | 2009-04-02 | — | — | US | disclosed |
| WO-2009005382-A3 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | CT BADAN MOLEKULAR I MAKRO (PL) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009005382-A2 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005382-A2 | DERIVATIVES OF NUCLEOSIDE-5'-O-HYPOPHOSPHATES AND THEIR MONO- AND DITHIOHYPOPHOSPHATE ANALOGUES AND THE PROCESS FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008125908-A2 | ENHANCED RETINAL DELIVERY OF A NUCLEIC ACID THROUGH IONTOPHORESIS | EYEGATE PHARMA S.A. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125116-A2 | UPAR INHIBITION | AARHUS UNIVERSITET (DK) | 2008-10-23 | — | — | WO | disclosed |
| EP-1981520-A2 | COMBINATION THERAPY FOR THE TREATMENT OF NEOVASCULAR DISORDERS | (OSI) Eyetech, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1919930-A2 | NEW NUCLEIC ACID BASE PAIRS | Dako Denmark A/S (DK) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008048128-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[(N- ACYL)AMIDOSELENOPHOSPHATE]-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048128-A1 | 5'-O-[(N-ACYL)AMIDOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDOTHIOPHOSPHATE]- AND 5'-O-[(N-ACYL)AMIDODITHIOPHOSPHATE]- AND 5'-O-[(N- ACYL)AMIDOSELENOPHOSPHATE]-DERIVATIVES OF NUCLEOSIDES AND PROCESSES FOR THE MANUFACTURE THEREOF | CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH, POLSKIEJ AKADEMII NAUK (PL) | 2008-04-24 | — | — | WO | disclosed |
| EP-1877433-A2 | VEGF VARIANTS | (OSI) EYETECH, INC. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070243548-A1 | Calumenin-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance | AURELIUM BIOPHARMA INC. (CA) | 2007-10-18 | — | — | US | disclosed |
| WO-2007087457-A2 | COMBINATION THERAPY FOR THE TREATMENT OF NEOVASCULAR DISORDERS | (OSI) EYETECH, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070178476-A1 | Detection of oligonucleotides by dual hybridization | OLDTECH, INC. | 2007-08-02 | — | — | US | disclosed |
| WO-2007072219-A2 | ALPHA ENOLASE-DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR CANCER AND CHEMOTHERAPEUTIC DRUG RESISTANCE | AURELIUM BIOPHARMA INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007072221-A2 | SURFACE MARKER-DIRECTED CANCER THERAPEUTICS | AURELIUM BIOPHARMA INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070122414-A1 | Surface marker-directed cancer therapeutics | AURELIUM BIOPHARMA INC. (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070122830-A1 | Prohibitin-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance | AURELIUM BIOPHARMA INC. (CA) | 2007-05-31 | — | — | US | disclosed |
| WO-2007045998-A2 | NEW NUCLEIC ACID BASE PAIRS | DAKO DENMARK A/S (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1776474-A2 | DETECTION OF OLIGONULEOTIDES BY DUAL HYBRIDIZATION | (OSI) EYETECH, INC. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20070077583-A1 | Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance | AURELIUM BIOPHARMA, INC. (CA) | 2007-04-05 | — | — | US | disclosed |
| US-20070066522-A1 | Tumor inhibition by modulating sprouty expression or activity | MICHIGAN STATE UNIVERSITY (US) | 2007-03-22 | — | — | US | disclosed |
| EP-1737497-A2 | NUCLEIC ACID APTAMERS CONJUGATED TO HIGH MOLECULAR WEIGHT STERIC GROUPS | (OSI) EYETECH, INC. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060286636-A1 | VEGF variants | OLDTECH, INC. | 2006-12-21 | — | — | US | disclosed |
| WO-2006119035-A2 | VEGF VARIANTS | (OSI) EYETECH, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006113579-A2 | TUMOR INHIBITION BY MODULATING SPROUTY EXPRESSION OR ACTIVITY | MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1660057-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | (OSI) EYETECH, INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-RE39112-E1 | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes | EISAI CO., LTD. (JP) | 2006-05-30 | — | — | US | disclosed |
| EP-1654362-A2 | 5'-AND 3'-CAPPED APTAMERS AND USES THEREFOR | EYETECH PHARMACEUTICALS, INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006012468-A2 | DETECTION OF OLIGONULEOTIDES BY DUAL HYBRIDIZATION | (OSI) EYETECH, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050260153-A1 | Facilitation of iontophoresis using charged moieties | OLDTECH, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050260651-A1 | Enhanced biologically active conjugates | OLDTECH, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005110489-A2 | NUCLEIC ACID APTAMERS CONJUGATED TO HIGH MOLECULAR WEIGHT STERIC GROUPS | (OSI) EYETECH, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1221444-B1 | FUSED IMIDAZOLE COMPOUNDS AND REMEDIES FOR DIABETES MELLITUS | EISAI CO LTD (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050096257-A1 | Administering platelet derived growth factor antagonist and endothelial growth factor antagonist | OPHTHOTECH CORPORATION | 2005-05-05 | — | — | US | disclosed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005020972-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | (OSI) EYETECH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005014814-A2 | 5’-AND 3’-CAPPED APTAMERS AND USES THEREFOR | (OSI) EYETECH, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-6841549-B1 | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus | EISAI CO., LTD. (JP) | 2005-01-11 | — | — | US | disclosed |
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | disclosed |
| CN-1166666-C | Fused imiazole compounds and remedies for diabetes mellitus | ������������ʽ���� | 2004-09-15 | — | — | CN | disclosed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | disclosed |
| US-6579868-B1 | Reacting a 2,6-dihalo-substituted purine compound with ammonia or an amine | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| EP-1054012-B1 | PURINE DERIVATIVES AND ADENOSINE A2 RECEPTOR ANTAGONISTS SERVING AS PREVENTIVES/REMEDIES FOR DIABETES | EISAI CO LTD (JP) | 2003-06-11 | — | — | EP | disclosed |
| EP-1300147-A1 | Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus | Eisai Co. Ltd (JP) | 2003-04-09 | — | — | EP | disclosed |
| CN-1365361-A | Condensed imidazole compound and drug for treating diabetes | EISAI CO LTD (JP) | 2002-08-21 | — | — | CN | disclosed |
| EP-1221444-A1 | FUSED IMIDAZOLE COMPOUNDS AND REMEDIES FOR DIABETES MELLITUS | Eisai Co., Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| EP-1054012-A1 | PURINE DERIVATIVES AND ADENOSINE A2 RECEPTOR ANTAGONISTS SERVING AS PREVENTIVES/REMEDIES FOR DIABETES | Eisai Co., Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
| EP-1054012-A1 | PURINE DERIVATIVES AND ADENOSINE A2 RECEPTOR ANTAGONISTS SERVING AS PREVENTIVES/REMEDIES FOR DIABETES | Eisai Co., Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (28 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252036-A1 | METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) | UBE2G2, UBE2N, UBE2E1 | PDPK1 1234/4885GDA 2663/4885CDK2 154/4885 |
| US-11001891-B2 | Methods for treating Parkinson's disease | SNCA, GBA3, LRRK2 | PDPK1 283/4885GDA 30/4885CDK2 3133/4885 |
| US-20170166891-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | HSP90AB1, HSP90AB2P, HSP90AA1 | PDPK1 586/4885GDA 3493/4885CDK2 3504/4885 |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885CDK2 3750/4885 |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | PDPK1 281/4885GDA 1170/4885CDK2 1757/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885CDK2 3750/4885 |
| US-20140179621-A1 | Methods for Treating or Preventing Ophthalmological Diseases | VEGFA, PDGFA, PGF | PDPK1 3318/4885GDA 1417/4885CDK2 2854/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885CDK2 3750/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PDPK1 3868/4885GDA 83/4885CDK2 4020/4885 |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PDPK1 3868/4885GDA 83/4885CDK2 4020/4885 |
| US-20150353930-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | HSP90AB1, HSP90AB2P, HSP90AA1 | PDPK1 736/4885GDA 2959/4885CDK2 3727/4885 |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885CDK2 3750/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885CDK2 3750/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885CDK2 3750/4885 |
| US-20090088721-A1 | Enhanced retinal delivery of a nucleic acid through iontophoresis | NR2E3, MITF, SLC5A11 | PDPK1 3931/4885GDA 1043/4885CDK2 3386/4885 |
| US-10023864-B2 | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta | HSP90AB1, HSP90AB2P, HSP90AA1 | PDPK1 736/4885GDA 2959/4885CDK2 3727/4885 |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | FLT4, TEK, FLT1 | PDPK1 4252/4885GDA 314/4885CDK2 2868/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PDPK1 3868/4885GDA 83/4885CDK2 4020/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PDPK1 3868/4885GDA 83/4885CDK2 4020/4885 |
| US-20220064732-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | SNCA, GBA3, LRRK2 | PDPK1 283/4885GDA 30/4885CDK2 3133/4885 |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885CDK2 3750/4885 |
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | VEGFA, PDGFA, PGF | PDPK1 3318/4885GDA 1417/4885CDK2 2854/4885 |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | NSUN2, RNGTT, NSUN3 | PDPK1 3868/4885GDA 83/4885CDK2 4020/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PDPK1 3533/4885GDA 36/4885CDK2 3750/4885 |
| US-20120184569-A1 | A3 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | ADORA3, ADORA1, ADORA2A | PDPK1 2789/4885GDA 353/4885CDK2 1677/4885 |
| US-20050260153-A1 | Facilitation of iontophoresis using charged moieties | ANXA11, SLC7A1, TRPC6 | PDPK1 4234/4885GDA 1634/4885CDK2 4040/4885 |
| US-20180135129-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | SNCA, GBA3, LRRK2 | PDPK1 283/4885GDA 30/4885CDK2 3133/4885 |
| US-20140154266-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | HSP90AB1, HSP90AB2P, HSP90AA1 | PDPK1 586/4885GDA 3493/4885CDK2 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.